Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome

Kidney International

Volumn 80, Issue 4, 2011, Pages 397-404

  Strobel, Stefanie ^a   Abarrategui Garrido, Cynthia ^b   Fariza Requejo, Elena ^b   Seeberger, Harald ^a   Sánchez Corral, Pilar ^b   Józsi, Mihály ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

autoantibody; complement; factor H; factor H related proteins; hemolytic uremic syndrome

Indexed keywords

AUTOANTIBODY; FACTOR H AUTOANTIBODY; FACTOR H RELATED PROTEIN 1; FACTOR H RELATED PROTEIN 3; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PLASMA PROTEIN; RECOMBINANT FACTOR H RELATED PROTEIN 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC UREMIC SYNDROME; CLINICAL ARTICLE; COMPLEX FORMATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; GENE MUTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IN VIVO STUDY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 80052272216     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.152     Document Type: Article

References (32)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
2. Sánchez-Corral P, Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010; 150: 529-542.
3. Zipfel PF, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3: e41.
4. Venables JP, Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006; 3: e431.
5. Dragon-Durey M-A, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563. (Pubitemid 41725154)
6. Jó zsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol 2008; 29: 380-387.
7. Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol 2002; 169: 4702-4706. (Pubitemid 35217129)
8. Jó zsi M, Oppermann M, Lambris JD et al. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol 2007; 44: 2697-2706. (Pubitemid 46240314)
9. Oppermann M, Manuelian T, Jó zsi M et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006; 144: 342-352.
10. Jó zsi M, Strobel S, Dahse H-M et al. Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110: 1516-1518.
11. Jó zsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514. (Pubitemid 351213440)
12. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010; 115: 379-387.
13. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009; 114: 4261-4271.
14. Dragon-Durey M-A, Blanc C, Marliot F et al. The high frequency of complement factor H-related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447-450.
15. Strobel S, Hoyer PF, Mache CJ et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25: 136-144.
16. Sánchez-Corral P, González-Rubio C, Rodr?́guez de Córdoba S et al. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004; 41: 81-84.
17. Jokiranta TS, Zipfel PF, Hakulinen J et al. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett 1996; 393: 297-302. (Pubitemid 26298114)
18. Lehtinen MJ, Rops AL, Isenman DE et al. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009; 284: 15650-15658.
19. Vaziri-Sani F, Holmberg L, Sjöholm AG et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006; 69: 981-988. (Pubitemid 43372172)
20. Abarrategui-Garrido C, Melgosa M, Peñ a-Carrión A et al. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008; 52: 171-180. (Pubitemid 351853263)
21. Heinen S, Hartmann A, Lauer N et al. Factor H related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114: 2439-2447.
22. Majno SA, Jokiranta TS, Hühn M et al. The human Factor H-related protein 1 (FHR-1) binds to C3b and heparin: implications for a regulatory role on the level of C3. Mol Immunol 2003; 40: 174 (abstract).
23. Haupt K, Kraiczy P, Wallich R et al. Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis 2007; 196: 124-133. (Pubitemid 46982746)
24. Ferreira VP, Herbert AP, Cortés C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009; 182: 7009-7018.
25. Heinen S, Sánchez-Corral P, Jackson MS et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006; 27: 292-293.
26. Kwon T, Dragon-Durey M-A, Macher MA et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008; 23: 2088-2090. (Pubitemid 351768178)
27. Lee BH, Kwak SH, Shin JI et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009; 66: 336-340.
28. Lionet A, Provô t F, Glowacki F et al. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. Nephrol Dial Transplant Plus 2009; 2: 458-460.
29. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180-2187.
30. Ferrari S, Scheiflinger F, Rieger M et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-2822. (Pubitemid 46482076)
31. Tumlin JA, Madaio MP, Hennigar R. Idiopathic IgA Nephropathy: Pathogenesis, Histopathology, and Therapeutic Options. Clin J Am Soc Nephrol 2007; 2: 1054-1061.
32. Mihlan M, Hebecker M, Dahse HM et al. Human complement factor H-related protein 4 binds and recruits native pentameric C-reactive protein to necrotic cells. Mol Immunol 2009; 46: 335-344.